Featured Research

from universities, journals, and other organizations

Low dose of targeted drug might improve cancer-killing virus therapy

Date:
June 16, 2014
Source:
Ohio State University Wexner Medical Center
Summary:
Giving low doses of the targeted agent bortezomib with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer with little added toxicity. The findings support the testing of this combination therapy in a clinical trial.

Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James).

Viruses that are designed to kill cancer cells -- oncolytic viruses -- have shown promise in clinical trials for the treatment of brain cancer and other solid tumors. This cell and animal study suggests that combining low doses of the drug bortezomib with a particular oncolytic virus might significantly improve the ability of the virus to kill cancer cells during oncolytic virus therapy.

The research is published in the journal Clinical Cancer Research.

"These findings pave the way for a treatment strategy for cancer that combines low doses of bortezomib with an oncolytic virus to maximize the efficacy of the virus with little added toxicity," says principal investigator Balveen Kaur, PhD, professor and vice chair of research, Department of Neurological Surgery and Radiation Oncology, and a member of the OSUCCC -- James Translational Therapeutics Program.

"Because bortezomib is already approved by the Food and Drug Administration, a clinical trial could be done relatively quickly to test the effectiveness of the drug-virus combination," Kaur says.

Bortezomib inhibits the activity of proteasomes, structures in cells that break down and recycle proteins. Kaur notes that blocking these "cellular recycling plants" activates a cellular stress response and increases the expression of heat shock proteins. This reaction, which can lead to bortezomib resistance, makes the cells more sensitive to oncolytic virus therapy with little additional toxicity.

For this study, Kaur and her colleagues used a herpes simplex virus-type 1 oncolytic virus. Key technical findings include:

  • One of the overexpressed heat-shock proteins, HSP90, facilitates oncolytic virus replication, enabling the virus to kill more tumor cells;
  • In a glioma model, the combination treatment suppressed tumor growth by 92 percent relative to controls and improved survival (six of eight tumors had completely regressed by day 23 after treatment);
  • Similar outcomes occurred in a head and neck cancer model.

"To our knowledge, this study is the first to show synergy between an oncolytic HSV-1-derived cancer killing virus and bortezomib," Kaur says. "It offers a novel therapeutic strategy that can be rapidly translated in patients with various solid tumors."


Story Source:

The above story is based on materials provided by Ohio State University Wexner Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Y. Yoo, B. S. Hurwitz, C. Bolyard, J.-G. Yu, J. Zhang, K. Selvendiran, K. S. Rath, S. He, Z. Bailey, D. Eaves, T. P. Cripe, D. S. Parris, M. A. Caligiuri, J. Yu, M. Old, B. Kaur. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects.. Clinical Cancer Research, 2014; DOI: 10.1158/1078-0432.CCR-14-0553

Cite This Page:

Ohio State University Wexner Medical Center. "Low dose of targeted drug might improve cancer-killing virus therapy." ScienceDaily. ScienceDaily, 16 June 2014. <www.sciencedaily.com/releases/2014/06/140616204544.htm>.
Ohio State University Wexner Medical Center. (2014, June 16). Low dose of targeted drug might improve cancer-killing virus therapy. ScienceDaily. Retrieved August 30, 2014 from www.sciencedaily.com/releases/2014/06/140616204544.htm
Ohio State University Wexner Medical Center. "Low dose of targeted drug might improve cancer-killing virus therapy." ScienceDaily. www.sciencedaily.com/releases/2014/06/140616204544.htm (accessed August 30, 2014).

Share This




More Health & Medicine News

Saturday, August 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins